Statin medications inhibit the enzyme hydroxymethylglutaryl–coenzyme A (HMG-CoA) reductase to lower low-density lipoprotein cholesterol to reduce both primary and secondary cardiovascular risk.
1 More than 200 million people worldwide are estimated to use statin therapy, which is generally well tolerated by most patients.
2 There are potential harms associated with statins, including well-known musculoskeletal adverse effects that include myalgia (estimated prevalence, 7%-29% of all statin users) and the rare, yet severe condition of rhabdomyolysis (incidence, 0.4 per 10 000 person-years).
2-4 In most instances these adverse effects resolve when statin treatment is discontinued. However, in the past 2 decades, numerous case reports have suggested that statins might also be associated with the development of inflammatory myositis.
5 A recent systematic review identified 16 publications reporting a total of 100 patients with statin-associated autoimmune myopathy.
6 These case reports have been further supported by a small case-control study from France
7 of 37 patients that reported a significant association between statin exposure and chronic muscle disease, including inflammatory myositis (odds ratio [OR], 2.73; 95% CI, 1.21-6.14), by comparison with population-based matched controls.
7